

## Fig. 2: Top 20 Prescription Drugs by US Sales '12

Rank	Product	Company	2012 Total (Billions)	2011 Total (Billions)
1	Nexium	AstraZeneca	\$6.0	\$6.4
2	Abilify	Otsuka/BMS	\$5.9	\$5.3
3	Crestor	AstraZeneca	\$5.1	\$4.6
4	Advair Diskus	GlaxoSmithKline	\$4.9	\$4.8
5	Cymbalta	Eli Lilly	\$4.7	\$3.8
6	Humira	Abbott*	\$4.6	\$3.7
7	Enbrel	Amgen	\$4.3	\$3.8
8	Remicade	Johnson & Johnson	\$3.9	\$3.5
9	Copaxone	Teva	\$3.6	\$3.2
10	Neulasta	Amgen	\$3.5	\$3.3
11	Singulair	Merck	\$3.3	\$4.8
12	Rituxan	Genentech/Roche	\$3.2	\$3.0
13	Plavix	Bristol-Myers Squibb	\$3.0	\$7.1
14	Atripla	BMS/Gilead	\$2.9	\$2.6
15	Spiriva Handihaler	Boehringer Ingelheim	\$2.8	\$2.5
16	Oxycontin	Purdue	\$2.8	\$2.9
17	Januvia	Merck	\$2.7	\$2.2
18	Avastin	Genentech/Roche	\$2.7	\$2.7
19	Lantus	Sanofi	\$2.3	\$2.1
20	Truvada	Gilead	\$2.3	\$2.0
<b>Total others</b>			<b>\$240.8</b>	<b>\$246.4</b>
<b>Total market</b>			<b>\$325.8</b>	<b>\$329.2</b>

Source: IMS Health, National Sales Perspectives

\*On January 2, 2013, Abbott's research-based pharma business, AbbVie, became a separate entity